[对慢性淋巴细胞白血病患者的COVID-19单中心研究]

X Lu1, L Gao2, S J Qian1

  • 1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.

概括

慢性淋巴细胞白血病 (CLL) 患者的COVID-19显示出严重感染率高,疫苗接种率低. 渐进性CLL和最近的抗CD20治疗增加了风险,而布鲁顿氨酸激酶 (BTK) 抑制剂单疗提供了保护.